Fig. 2

Daily difluorosamine treatment for 5 days reduces neurocan and promotes functional recovery in ICH. A Chemical structure of difluorosamine. B Experimental paradigm. C, D Graphs comparing the latency of rota-rod (C) or forelimb force of grip strength (D) tests between control and DIF mice; each black circle is a different mouse across 3 separate experiments (n of 6, 6 or 8 in each of the experiment per group; N = 20 total). E Representative confocal images of perihematomal area (left) and lesion core (right) at day 7 in control and DIF mice stained for neurocan (red), Iba1(green), GFAP (blue). The lower left corner inside the dotted lines is the lesion core. Scale bar = 50 μm. F Bar graphs comparing the levels of neurocan in perihematomal area, lesion core and contralateral area at day 7 (N = 6). Data are mean ± SEM and analyzed by two-way ANOVA-Tukey’s post hoc test. Western blot analysis (N of 4) of neurocan (G) and quantification (H) comparing the signal ratio of neurocan to β-actin among sham, control, and DIF mice; mean ± SEM, one-way ANOVA-Tukey’s post hoc test; ns: not significant. Significance indicated as **p < 0.01, ***p < 0.001